Funding for this research was provided by:
Pfizer Inc. (Grant ID 34580627)
Medical University of Vienna
Received: 2 December 2021
Accepted: 15 February 2022
First Online: 21 March 2022
Conflict of interest
: A. Dan, E. Bicakcic, G. Fabian, Z. Kahan, G. Penthedourakis, J. Sgouros, C. Thallinger and A. Wrona declare that they have no competing interests. L.N. Gales declares lecture fees from Actavis, Angelini, Amgen, AstraZeneca, Astellas, BMS, Boehringer, Bayer, Ipsen, J&J, Magnapharm, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Sandoz, and Servier. M. Mencinger declares honoraria/lecture fees from BMS, Janssen, Astellas, Roche, Pfizer, Sanofi, Amgen, Bausch Health, and Novartis. C.G. Kuhar declares honoraria/lecture fees from Roche, Pfizer, Novartis, Lilly, MSD, LEK, KRKA, Merck, Bayer, and BMS. D. Sirbu declares honoraria/lecture fees from BMS, Novartis, Pfizer, Roche, Ipsen, AstraZeneca, Sandoz, Lilly, Astellas, and Merck. U. Janzic declares honoraria/lecture fees from MSD, Pfizer, Roche, AstraZeneca, Boehringer Ingelheim, and Takeda. P. Berzinec declares grants from Roche; honoraria/fees from Amgen, Bayer, Roche, and Takeda; participation in a company sponsored speaker’s bureau from AstraZeneca, Boehringer Ingelheim, and MSD. M. Vosmik declares grants from BMS; honoraria/fees from BMS, MSD, Sanofi, Eli Lilly; participation in a company sponsored speaker’s bureau from BMS, MSD, and Sanofi. C. Zielinski declares honoraria/fees from Athenex, MSD, Imugene, AstraZeneca, Servier, and Eli Lilly. L. Simetic declares grants from MSD, Novartis, BMS, Genesis Pharma, and Roche; honoraria/fees from MSD, Novartis, BMS, Genesis Pharma, and Roche.